
Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
10.1136/medethics-2017-104718
10.1136/medethics-2017-104718

Link to publication record in Explore Bristol Research
PDF-document

This is the final published version of the article (version of record). It first appeared online via BMJ at http://jme.bmj.com/content/early/2018/05/16/medethics-2017-104718. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research
General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms
**PAPER**

**Charlie Gard and the weight of parental rights to seek experimental treatment**

Giles Birchley

**ABSTRACT**

The case of Charlie Gard, an infant with a genetic illness whose parents sought experimental treatment in the USA, brought important debates about the moral status of parents and children to the public eye. After setting out the facts of the case, this article considers some of these debates through the lens of parental rights. Parental rights are most commonly based on the promotion of a child’s welfare; however, in Charlie’s case, promotion of Charlie’s welfare cannot explain every fact of the case. Indeed, some seem most logically to extend from intrinsic parental rights, that is, parental rights that exist independent of welfare promotion. I observe that a strong claim for intrinsic parental rights can be built on arguments for genetic propriety and children’s limited personhood. Critique of these arguments suggests the scope of parental rights remains limited: property rights entail proper use; non-personhood includes only a small cohort of very young or seriously intellectually disabled children and the uniqueness of parental genetic connection is limited. Moreover, there are cogent arguments about parents’ competence to make judgements, and public interest arguments against allowing access to experimental treatment. Nevertheless, while arguments based on propriety may raise concerns about the attitude involved in envisioning children as property, I conclude that these arguments do appear to offer a prima facie case for a parental right to seek experimental treatment in certain limited circumstances.

**INTRODUCTION**

The case of Charlie Gard concerned the right of parents of an infant with a genetic illness to take him to the USA to receive experimental treatment against medical advice. In July 2017, a spokesperson for the family announced that frustrating this right amounted to Charlie being ‘taken prisoner by the NHS’.

In this article, I consider the basis and scope of parental rights (PR) in relation to the details of Charlie’s case, primarily drawn from the legal records. Discussion of moral rights is justified here because these should be accounted for in future cases. Further, moral rights can translate to legal rights, and thus may ultimately compel particular decisions. I argue that, although the case was decided on welfare grounds, there is evidence of attention to rights of Charlie’s parents that are independent of a welfare basis—that I shall term ‘intrinsic PR’. Exploring the basis of such rights, I suggest that the strongest philosophical argument for PR is that Charlie was a non-person and genetically his parents’ property. These rights are strictly limited, and in Charlie’s case PR were outweighed by a precautionary approach to the uncertain harms accruing to Charlie. However, in future similar cases, PR may prove determinative where harms are excluded and potential benefits are great. I argue that parents are competent to exercise these rights, and that public interest concerns over access to experimental treatment can be allayed.

**CHARLIE’S CASE**

Charlie was born with infantile-onset mitochondrial DNA depletion syndrome (MDDS). MDDS is a genetic disease where abnormal mitochondrial DNA causes cells to malfunction. Different strains of MDDS cause variable levels of disability. Charlie’s rare ‘RRM2B’ mutation of MDDS caused progressive brain and muscle damage.

Charlie was admitted to hospital at 2 months. A ventilator helped him to breathe and he had recurrent seizures. He could not move his limbs and open his eyes only intermittently, making it difficult to tell when he was in pain. Charlie’s parents became aware of experimental treatment (nucleoside therapy), where biochemical food supplements stimulate the repair of mitochondrial DNA. Results of nucleoside therapy on mice with the TK2 variant of MDDS (which usually leaves the brain unaffected) increased lifespan slightly. Human trials saw 13 (of 18) children with TK2 MDDS grow, and one improve their walking ability over 4 years. There was no evidence the therapy repaired the brain, nor was it tried on RRM2B MDDS. Nevertheless, a US expert claimed it might help Charlie.

Charlie’s doctors agreed to try the therapy. However, before a trial commenced, Charlie suffered several weeks of refractory epileptic fits. This caused severe brain damage and Charlie’s doctors believed he had no hope of improvement, counselling fatal withdrawal of ventilation. Charlie’s parents remain steadfast in their wish for further treatment, including nucleoside therapy. The hospital sought a court order that it would be lawful to withdraw treatment because treatment was not in Charlie’s best interests. Charlie’s parents argued that they knew Charlie best, and cared for him more deeply than anyone else. Yet, apart from Charlie’s parents and the clinician offering treatment, all witnesses agreed with Charlie’s doctors. The order the hospital sought was eventually granted, and affirmed in three subsequent appeals.

A final spate of litigation settled when and where withdrawal would take place. Charlie’s parents bitterly complained that the outcome left...
them ‘very little time’ before Charlie died. Withdrawal did not take place immediately, but after an unspecified period of time set out in a confidential annexe to the court order. Evidently, this was brief as reports of Charlie’s death were published after 18:00 the following day.

PR AND THE LIMITATIONS OF WELFARE

Broadly speaking, a right may be seen as a way of empowering an individual against collective goals that disregard that individual’s legitimate interests. Moral rights are normative claims supportable by reasoned arguments. Legal rights can be (and often have been) argued for on the basis of a putative moral right. Legal rights may impose binding duties on others to either enable or, more commonly, not to impede the exercise of that right. The potential to influence the actions of decision-makers makes it pertinent to consider moral rights when assessing whether Charlie’s case should alter our attitudes to the parental role in decision-making in similar cases.

In disputes about children’s care “[m]any of today’s critics of children’s rights are passionate defenders of … the rights of parents”; different ethical approaches to children and parents make asymmetric claims about the putative moral rights of both parties. Arguments about rights may suggest that children: have rights; have rights that others (especially parents) should articulate; do not have rights. That parents: have rights based on their ability to advance the welfare of their child(ren); have rights over their children that are intrinsic to their status as parents. Broadly speaking (and leaving aside thornier issues of competence), my speaking (and leaving aside thornier issues of competence), my

...
account overcomes the regress problem. I suggest an account on PR based on this reasoning, prima facie, fairly strong. In the next section of this article, I critique this account to determine some limits of intrinsic PR.

**THE LIMITS OF INTRINSIC PR**

I have postulated a basis for intrinsic PR relies on two key elements: genetic propriety and children’s non-personhood. The scope of PR depends on the strength of these elements.

An obvious objection to this account is that children ought not to be described as property. An extraordinary range of commentators take pains to emphasise this position. One basis given for this claim is that it harms children to be treated as property. Yet proprietarians argue that parents are still be bound to treat their children non-malevolently. Restrictions against misuse are a well-argued feature of legitimate property rights, including an obligation not to use property to harm others. Lyons argues that misuse of children could be prohibited by classing them as inalienable property, and this suggests the obligation against harm could extend to the child themselves. Argued this way, some consider the consequences of proprietarianism are proximate to the welfare view of PR. While describing children as property may evoke concern, it is difficult to devise a convincing argument against PR founded solely on this basis. Nevertheless, we should note that the scope of proprietary PR is restricted, although based on avoiding harm and misuse, rather than promoting welfare.

The proprietarian account appears more vulnerable in claiming that children are non-persons. The non-personhood claim coheres with widespread public intuitions that the life of a fetus is less morally important than the woman who carries it. Without consideration of the moral status of fetuses here, these intuitions at least suggest arguments using personhood should be seriously considered when asserted in relation to older children. However, even if we accept that personhood is morally legitimate, it is arguable that under common personhood criteria, most children are persons, suggesting further limits to the scope of PR. Based on criteria of futurity and self-awareness, Singer argues children in the neonatal period (<1 month) are non-persons. Ross suggests that children up to late adolescence are not capable of rational decisions and thus ‘not full Kantian persons’. There is evidence that disputes these assumptions. Neonates appear to anticipate familiar events and distinguish their own touch and cry. This suggests neonates may possess a sense of futurity and self-consciousness—meeting Singierian criteria for personhood. Further, interviews with chronically ill children and their clinicians suggest that children as young as 3 years old may be capable of making rational decisions, challenging Ross’ claims. On this basis, parents’ rights over their children arguably begin waning between a few days and a few years after birth. However, PR may be much more persistent in children who are severely intellectually disabled, like Charlie.

A final criticism of proprietarianism, which may further reduce the scope of PR, is based on criticism of genetic propriety. If parental property rights stem from parental ownership of the child’s genetic information, it appears to support the claim that genetically related parents should have a greater say in decisions about their child than non-genetically related parents, such as adoptive parents. Yet it seems unconvincing to suggest this when the genetic parents have no interest in, care for, or knowledge of, their child. Even if we disregard these objections, genetic similarity seems a fragile basis on which to base exclusively parental rights. Although familial resemblances are commonly cited as important flags of identity, it is by no means clear that these socially constructed meanings rest on genetic resemblances rather than being proxies of social connection. The global population has extensive genetic similarity: otherwise unconnected individuals have vastly more genetic information in common than they do not. Genetic propriety accounts rest on a very slender material basis for such a connection between the child and the parent. Indeed, taken proportionately, it may also imply a shared genetic propriety of children. If the proportion of unique parental property in children is discernible, but very small, perhaps the rights of parents that can derive from this property are proportionately small.

These arguments do not suggest that intrinsic PR cannot be made out. However, the scope of these rights is restricted. By being based on a property right they limit the PR to non-harmful acts. On the most generous account the emergent personhood of the child causes intrinsic PR to expire after a few years in most cases. Finally, intrinsic PR based on genetic propriety are little greater than the rights of unrelated humans. These tangible, but weak, reasons for intrinsic PR may support transient delays in securing their child’s welfare. However, they are unlikely to be strong enough to allow parents to undertake prolonged acts against their child’s well-being.

**LOOKING TO THE FUTURE: PR TO ACCESS TO EXPERIMENTAL TREATMENT**

Given the justifiable, but slim, bases for PR, one of the considerations to arise from Charlie’s case is to ask under what circumstances PR could influence future cases about accessing experimental treatment. Having established that PR beyond those based on enhancing the welfare of the child are both weak and limited, crucial to such questions will be the harms and benefits likely to arise from experimental treatment. The experimental basis means benefits will be uncertain. Indeed, a defining feature of potentially fatal cases involving critically ill children is the disagreement about whether the same outcome is a harm or a benefit. On one side, living with intensive care may be understood to amount to harm, and death a benefit; on the other side, loss of life is the greatest harm, and continued intensive care is a benefit. This disagreement is additionally complicated by the uncertain outcomes of experimental treatment. In Charlie’s case, the risks of experimental treatment alone (a food supplement) were inconsequential. Intrinsic PR combined with uncertain and minimal potential benefit (because of Charlie’s brain injuries) were too weak to overcome the presence of uncertainty about harms, and a precautionary approach was taken. By precautionary approach, I mean broadly, the exercise of the principle of precaution, where uncertainty about the harms and risks that arise from a technology new to science means we should err on the side of caution. While I lack space to offer detailed argument, such an approach has been cogently argued to be pertinent to the regulation of innovation in health-care and neonatal non-treatment. Yet the ability to overcome reservations about uncertainty in pursuit of potentially great benefits may be a feature of intrinsic PR. In future cases where harm is minimal and benefits are uncertain, but potentially great, intrinsic PR may be determinative. However, there are other objections to accessing experimental treatment. First, are parents competent to make these judgements? Second, are there public interests grounds on which to deny competent demands? If parents have rights to demand experimental treatment, an additional concern is whether they can rationally exercise these rights. Questioning the ability of terminally ill persons to make
rational judgements about experimental treatment, Caplan argues that terminally ill people are likely to view any experimental treatment with undue optimism. The moral weight of these elements changes where the patient is a child. The question of parental competence to decide is a thorny one. The challenges to parental competence are clear if we consider Charlie’s case, where Charlie’s parents were vulnerable to manipulation by third parties. These emotional challenges lead some to question the ability of parents to offer meaningful consent in life and death situations. Yet the enormity of parental bereavement suggests that the degree of parental incompetence should be extreme indeed, if it is to over-rule a parental right of say (in practice, this circle is of course squared by the current legal process, which allows the courts to make a decision if parents and clinicians disagree).56

Bender et al57 offer public interest arguments for restricting access to experimental treatments. They argue that premature access to experimental treatments may raise false expectations among those with similar illnesses, igniting public demand. If this demand is not resisted, drugs may be made widely available before their effectiveness is proven, leading to potentially ineffectve treatments becoming the standard of care. The authors also argue that early access to unproven drugs may both hamper recruitment to, and reduce industry incentives to run, clinical trials. First, recruitment is hampered because early access physically reduces the number of potential drug trial participants. Second, if drug companies are paid for access unproven drugs, it provides a commercial disincentive for clinical trial sponsorship. Not only are trials costly and time consuming, but the fact they risk jeopardising a proven source of profit if the experimental treatment proves ineffective provides a clear conflict of interest. These arguments suggest that, whatever the benefit to the patient, early access has opportunity costs, because inadequate knowledge of effectiveness denies future patients access to treatments with a proven basis. Ultimately there is a price to pay beyond the risks and benefits to an individual patient. However, preventing the exercise of individual choice to protect public interests may appear to be a paradigm case of group interests impinging on individual interests. This is what rights are designed to prevent. Certainly, it has been argued that where patients seek innovative lifesaving treatments a rights approach requires that any prohibition on treatment must be undergirded by extremely weighty risks if they are to defensively outweigh the patient’s right to life.58

The choice of patients who are terminally ill to access treatment may carry enough moral weight to overcome objections in the public interest. The weakness of PR alters the dynamics of such choices when the choice is a parental one. My analysis suggests that in a future case intrinsic PR could overcome uncertainty in the face of large potential benefits. Certainly, the English courts have in the past allowed access innovative treatment in such circumstances without an obvious prohibition in the public interest.59 Indeed, with the right approach these factors could be mitigated further in a future similar case to Charlie’s. There is little prospect of clinical trials on a rare mutation like RRM2B. Early access linked to a robust, if novel, trial design may accelerate understanding of the experimental drug, and thus allay public interest concerns. It is notable in Charlie’s case that no evidence was advanced that access was to be part of such a trial. Public interest concerns may therefore have placed additional obstacles in the way of PR in Charlie’s case.

CONCLUSION

Charlie’s case brought questions about the moral status of parents and children into the public eye. The case apparently fell on welfare grounds; however, not every fact of the case is consistent with the promotion of Charlie’s welfare. Reviewing the grounds for intrinsic PR that are independent of the welfare of their child, I suggest the strongest of these lie in arguments for genetic propriety and children’s non-personhood. Critiquing these claims suggests limits to intrinsic PR. Nevertheless, I argue that these claims provide grounds to accept PR for experimental treatment in future cases involving children who cannot contribute an opinion. These cases must involve no harm to the child and benefits, despite being uncertain, must be potentially great. Further, I argue parents are competent to exercise these rights, and that objections in the public interest may be overcome by evidence of robust trial design in the experimental treatment.

Acknowledgements Thanks to the Welcome Trust for funding both a Biomedical Ethics for Health Professionals and Scientists for the ‘Judging Best Interest in Paediatric Intensive Care (BIPIC)’ project (WT097725MF) and a Seed Award for the ‘Best Interests in Medical Ethics and Law (BABEL)’ project (110076/Z/15/Z), during which bulk of the research in this paper was undertaken. Special thanks to Richard Huxtable as PI of the second project.

Contributors GB is the sole author of the manuscript.

Funding This study was funded by the Welcome Trust (grant nos. WT097725MF and 110076/Z/15/Z).

Disclaimer GB remains responsible for any errors or omissions herein.

Competing interests During the Charlie Gard case, GB made a statement to the Science Media Centre expressing an opinion about the case, which was circulated to the news media.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018 All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1 Johnson L. Charlie Gard ‘is being held prisoner by the NHS’ – family spokesman blasts authorities. Daily Express 2017.
4 Gard and Others v UK (2017) ECHR 39793-17.
Theoretical ethics

50  Pearson GA. Intensive care: because we can or because we should? *Arch Dis Child* 2018;archdischild-2017-314731.
54  Mostroux A. Publicity that was not always in the family’s interests; an investigation raises questions over how well the parents were guided by three key figures. *The Times* 2017–7–9.